Professor Petra Hamerlik is an accomplished researcher in primary pharmacology and brain cancer research. She earned an M.Sc. in Molecular Biology from Comenius University, Bratislava, Slovakia in 2005, followed by a PhD in Medical Biology from Palacky University Olomouc, CZ in 2008. Petra completed her postdoctoral training from 2008 to 2012, receiving education from various institutions in the UK, USA, and Denmark. In 2012, she was appointed as a Group Leader at the Danish Cancer Society and took on the role of Associate Professor at the University of Copenhagen, a position she maintained until 2020. During this time, Petra was honoured with several prestigious awards, which aided her in developing an independent research program centred on enhancing the understanding of DNA damage response (DDR.) regulation and its effects on genomic instability in glioblastoma, a deadly type of brain cancer. In August 2020, Petra joined AstraZeneca in Cambridge UK, as a Director and a Principal Scientist in Early Oncology to lead the DDR.i Drug discovery programs for brain tumours. In September 2022, Petra was recruited by the University of Manchester as the Inaugural Brain Tumour Charity Chair of Translational Neuro-Oncology. Her current work is focused on identifying novel treatments and early detection of intracranial tumours.
“I am honoured to join the Scientific Advisory Board of the Cure Brain Cancer Foundation. I look forward to collaborating with leading experts to advance research and treatments for brain cancer.”
